Candel Therapeutics (NASDAQ:CADL) Cut to Neutral at Bank of America
Bank of America downgraded shares of Candel Therapeutics (NASDAQ:CADL – Free Report) from a buy rating to a neutral rating in a research report report published on Wednesday, Marketbeat.com reports. The brokerage currently has $7.00 price objective on the stock, down from their prior price objective of $13.00. Several other research analysts also recently weighed […]
More Stories
Shooting at Poland Market Kills at Least 5
By Jacki Thrapp At least five people were killed when a gunman opened fire at a market in Poland on...
Portugal’s Cristiano Ronaldo Announces International Retirement
By The Associated Press Cristiano Ronaldo won’t play for Portugal anymore, ending on Thursday a career that spanned six World...
IRS Unveils 2027 Federal Income Tax Brackets
By Naveen Athrappully Federal tax authorities announced higher income tax brackets and other annual inflation adjustments for tax year 2027....
US Economy Adds 165,000 New Jobs in October, Unemployment Rate Dips to 4.1 Percent
By Andrew Moran Employment conditions strengthened in October as job growth blew past economists’ forecasts and the unemployment rate unexpectedly...
Trump Blames Democrats’ Midterm Victory for Stock Market Losses
By Jack Phillips President Donald Trump on Thursday said a stock market drop that day was due to Democrats winning...
Victor Davis Hanson Discusses What’s Next for GOP, Possible 2028 Contenders
By Timothy Frudd and Jan Jekielek President Donald Trump can still wield considerable political power over the next two years...